Eli Lilly backs away from Bace but not from novel Alzheimer’s targets

Eli Lilly’s ousting of two more early-stage Alzheimer’s projects is at least a sign that the group has taken to heart the “fail faster” philosophy that could keep it from repeating the mistakes of the unsuccessful solanezumab programme.